Pathogenesis and management of adenoviral keratoconjunctivitis

Figures & data

Table 1 Overview of ocular involvement and clinical manifestations with specific adenoviral serotypes^{2,8–10,12–14,37,41,99,100,106,110}

Ocular structure	Clinical manifestations	Subtypes involved
Adnexa	Eyelid edema, lacrimal gland enlargement, nasolacrimal duct inflammation	1-5,7,8,19,37,53,54
Conjunctiva	FollicleSj hyperemiaj edema, petechial hemorrhages, pseudomembranes	1-5,7,8,19,37,53,54
Cornea	Multifocal punctate keratitis, subepithelial infiltrates	8,19,37,53,54

Figure 1 Slit-lamp photography of superior palpebral conjunctiva with petechial hemorrhages (black arrow) in a patient with adenoviral keratoconjunctivitis.

Note: Courtesy of DeGaulle I Chigbu.

Figure 2 Slit-lamp photography of inferior palpebral conjunctiva with pseudomembrane (black arrow) in a patient with adenoviral keratoconjunctivitis.

Note: Courtesy of DeGaulle I Chigbu.

Figure 3 Flowchart highlighting management efforts for EKC patients.^{2,121–123,127,141,143}

Abbreviations: EKC, epidemic keratoconjunctivitis; SEIs, subepithelial infiltrates.

Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015;60(5):435–443.

 PubMed Web of Science ®Google Scholar

Muller MP, Siddiqui N, Ivancic R, Wong D. Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. Am J Infect Control. 2018;46(5):581–583.

 PubMed Web of Science ®Google Scholar

Meyer-Rusenberg B, Loderstadt U, Richard G, Kaulfers PM, Gesser C. Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch Arztebl Int. 2011;108(27):475–480.

 PubMed Web of Science ®Google Scholar

Clement C, Capriotti JA, Kumar M, et al. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Inves Ophthalmol Vis Sci. 2011;52(1):339–344.

 PubMed Web of Science ®Google Scholar

Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009;26(8):776–783.

 PubMed Web of Science ®Google Scholar

Levinger E, Trivizki O, Shachar Y, Levinger S, Verssano D. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(5):811–816.

 PubMed Web of Science ®Google Scholar